The short version of prohibited list fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-13. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Factor XIII, or fibrin stabilizing factor, is a plasma protein and zymogen. It is activated by thrombin to factor XIIIa which crosslinks fibrin in coagulation. Deficiency of XIII worsens clot stability and increases bleeding tendency. Human XIII is a heterotetramer. It consists of 2 enzymatic A peptides and 2 non-enzymatic B peptides. XIIIa is a dimer of activated A peptides.
== Typical technique == A sample is introduced, either manually or with an autosampler, into a sample loop of known volume. A buffered aqueous solution known as the mobile phase carries the sample from the loop onto a column that contains some form of stationary phase material. This is typically a resin or gel matrix consisting of agarose or cellulose beads with covalently bonded charged functional groups. Equilibration of the stationary phase is needed in order to obtain the desired charge of the column. If the column is not properly equilibrated the desired molecule may not bind strongly to the column. The target analytes (anions or cations) are retained on the stationary phase but can be eluted by increasing the concentration of a similarly charged species that displaces the analyte ions from the stationary phase. For example, in cation exchange chromatography, the positively charged analyte can be displaced by adding positively charged sodium ions. The analytes of interest must then be detected by some means, typically by conductivity or UV/visible light absorbance. Control an IC system usually requires a chromatography data system (CDS). In addition to IC systems, some of these CDSs can also control gas chromatography (GC) and HPLC.
Aura is a 5–60 minute neurological event that generally occurs just before the onset of the headache. Symptoms can be visual, sensory, or motor in nature. Visual effects occur most frequently, in as many as 99% of cases involving aura. In rare cases known as persistent aura, aura symptoms may remain after 60 minutes. Visual disturbances often consist of a scintillating scotoma or flickering in someone's field of vision that may interfere with their ability to read or drive. This typically starts near the center of vision and then spreads out to the sides with jagged or zigzagging lines. Lines are usually black and white, but may also appear colored. Some people lose part of their field of vision, while others experience blurring. Sensory auras are the second most common type of aura; they occur in 30–40% of people with auras. A feeling of pins-and-needles may begin on one side in the hand and arm and spread to the nose and mouth area on the same side. Numbness usually occurs after the tingling has passed, with a loss of position sense. Other symptoms of the aura phase can include speech or language disturbances, world spinning, and, less commonly, motor problems. Motor symptoms indicate a hemiplegic migraine, and weakness often lasts longer than one hour unlike other auras.
Sources: en.wikipedia.org
=== Dry co-micronization === Dry co-micronization is a nanomilling approach in which the drug substance is milled in a dry state together with GRAS excipients in a single unit operation. The excipients form a protective dispersion matrix around the sub-micron drug particles, preventing the surface-energy-driven reaggregation that otherwise dominates dry submicron powders, and yielding a free-flowing powder that can be tableted or encapsulated without further drying or downstream processing. The most widely commercialized dry co-micronization platform is SoluMatrix Fine Particle Technology, developed by iCeutica and acquired in 2011 by Iroko Pharmaceuticals. The platform has been used to formulate three U.S. Food and Drug Administration–approved low-dose non-steroidal anti-inflammatory drugs: Zorvolex (diclofenac, approved October 2013), Tivorbex (indomethacin, approved February 2014), and Vivlodex (meloxicam, approved October 2015). Each product was approved at a total daily dose 20–35% below the equivalent conventionally-formulated NSAID, on the basis that the increased dissolution rate of sub-micron particles permits comparable analgesic efficacy at lower systemic exposure. Unlike wet media milling, dry co-micronization requires no aqueous suspension or downstream drying step, shortening the unit-operation chain at the cost of constraining the formulation to excipients compatible with high-energy dry impact.
For his work, Alexander Bogomolets received in 1941 the Stalin Prize, which for Soviet scientists of those years was even more important than the Nobel Prize. 1938 The first specialized society dedicated to the study of aging. It was formed in Germany, Leipzig and was named the German Society for Aging Research (German: Deutsche Gesellschaft für Altersforschung, soon renamed to Deutsche Gesellschaft für Alternsforschung). The founder is Max Bürger. He also established the specialized journal Zeitschrift für Altersforschung – it is already the third such journal in the world after the previously mentioned Japanese and Romanian journals. 1938 The world's first scientific conference on aging and longevity in 1938 in Kiev, that was convened by Alexander Bogomolets. 1939 In the United Kingdom, the British Society for Research on Ageing is formed. The founder is Vladimir Korenchevsky who emigrated there from the former Russian Empire.
zygonema Also zygotene stage. In meiosis, the second of five substages of prophase I, following leptonema and preceding pachynema. During zygonema, synapsis occurs, physically binding homologous chromosomes to each other, and the cell's centrosome divides into two daughter centrosomes, each containing a single centriole.
In the quarterfinals, he beat Borna Ćorić in four sets to reach his second major semifinal. There, he lost the first two sets to Pablo Carreño Busta, but came back to win the match in five; this was his first-ever match win from two sets down. He thus advanced to his first major final, where he faced Dominic Thiem. He became the runner-up, losing the final in a final-set tiebreaker despite leading by two sets and twice coming within two points of the title in the final set. Zverev was seeded 6th at the French Open. He beat Dennis Novak, Pierre-Hugues Herbert, and Marco Cecchinato, before losing in four sets to Jannik Sinner. In October, he won two consecutive ATP 250 events in Cologne, which took place in the 2020 ATP Tour because of the cancellation of several tournaments due to the COVID-19 pandemic. In the finals, he defeated Félix Auger-Aliassime and Diego Schwartzman, both in straight sets. Zverev then reached the final of the Paris Masters, beating Nadal in straight sets in the semifinals, where he lost to Daniil Medvedev in three sets. In the ATP Finals, Zverev was eliminated in the group stage after a three-set win over Diego Schwartzman, and straight-set losses to Djokovic and the eventual champion Medvedev.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.